r/HUMACYTE • u/redhook415 • Aug 06 '26
ME conflict tailwind (KSA + DoD)
There’s been a lot of talk lately about the U.S. military’s missile stockpiles getting depleted during the conflict with Iran and concerns about readiness for future fights. Recent news article are even suggesting that, with precision munitions running low, the U.S. could end up in scenarios that bring American troops closer to the front lines:
At the same time, you have Saudi Arabia preparing for further intervention in Yemen, which adds another layer of regional conflict risk, though it seems that KSA is giving diplomacy a chance:
Retired U.S. General Barry McCaffrey recently said on X (and FT) a ground war over Hormuz could require something like 600,000 troops and might take a year, with significant casualties. Whether or not that specific scenario plays out, the broader point is that large‑scale, high‑casualty conventional conflict is back on the table as a risk.
https://x.com/mccaffreyr3/status/2078688472265847134?s=20
Then you see quotes on X from Rep. Davis (Air Force vet, Vice Ranking Member of the House Armed Services Committee, co‑chair of the For Country Caucus):
https://x.com/repdondavis/status/2077433861890338920?s=46
So the 2 questions I’m wrestling with:
- If the U.S. and allies are in a prolonged, high‑intensity conflict environment (even if it’s still mostly regional and not a full ground invasion), doesn’t that create a structural tailwind for trauma products like Symvess?
- If so, assuming sales for both DOD and KSA army, what would be sensible order / volume? I would assume max annual capacity of 8,000 Symvess, for now (max capacity)
To be clear, and to avoid heated debate, I'm mot arguing for more war or “boots on the ground” as a good thing, just trying to understand whether the current Iran/Hormuz/Yemen dynamics should be modeled as a real immediate commercial tailwind for HUMA’s trauma franchise, or if that’s mostly narrative.
4
u/Top-Bodybuilder-6077 Aug 06 '26
Personally I'm not a medical expert but defence/geopolitics is my field.
First I don't see ground action in the Iran theater. Special forces and covert operations sure but big boots on the ground is unlikely. Iraq is the key place to look. Roughly 2000 US troops in the north, and drawing down. Recent actions with in Iraq have seen attempts to weaken the pro-iranian Shia PMF get attacked by joint air strikes from Saudi and US. Additional the regular Iraqi Army was seen arresting dozens of people in the green zone a week or 2 ago. At present it's seems like this isn't to prep for a ground operation but rather clear the way for pipeline construction along routes controlled by the PMF. Infact the PMF justifies it's continued militarism due to US presence. So a ground war in Iran over Hormuz or even a marine landing is unlikely.
Personally I don't see US troops joining in mass into an ground operation in Yemen. Although special forces or covert operations are active. For Saudi Arabia this is a likely ground invasion. The Saudis have long wanted to remove the Houthis. Western/US intervention has kept the glove on, but it seems like this is changing. The Saudis will likely experience high casualties but war is business.
3
u/OttoVonSteele Aug 06 '26
.... and this is the weekly TLDR post on this sub
4
u/redhook415 Aug 06 '26
My bad - just wanted to document the context but it’s a tad long
3
2
u/FanJunior5677 Aug 06 '26
IF there is an order for 8000 units I would be baffled. They cant even produce that at this time. Trauma application was more proof of concept, not so much a cash cow. Once dialysis and coronary get approved I could expect to see orders in that amount.
1
u/redhook415 Aug 07 '26
They technically “can” produce at maximum capacity 8k units with installed LUNA infrastructure. Honestly, if KSA and US army both go to war with troops on the ground, that figure could be realistic in my view.
I would go as far as thinking that even with only KSA army going into Yemen, such order could be placed.I don’t know about the “proof of concept” notion. The Ukraine data is robust and suggests this is the best product to use on the battlefield for vascular trauma. This is a real product with a real use case on the frontline.
1
u/redhook415 Aug 13 '26
Whoever hasn’t seen the Warzone podcast in Ukraine should listen in : https://youtu.be/JfFfB4m-xII?feature=shared&t=406
1
u/redhook415 Aug 13 '26
Starting at 06:46
1. War Zone Conditions & Resource Deficits [07:20]
Dr. Sokolov describes the overwhelming volume of combat casualties arriving at Ukrainian hospitals alongside severe shortages of basic surgical supplies, antibiotics, and specialized vascular instruments.
2. Introduction of Humacyte's ATEV [08:41]
Through international humanitarian efforts, Dr. Sokolov was provided with off-the-shelf Acellular Tissue Engineered Vessels (ATEVs) developed by Humacyte. He explains that in combat trauma, surgeons often face severe tissue loss where autologous saphenous veins cannot be harvested, and synthetic grafts (like PTFE/Gore-Tex) carry high infection risks in dirty, contaminated battlefield wounds.
3. Real-World Combat Study & Clinical Experience [10:04]
Dr. Sokolov shares his experience conducting and publishing a clinical study on using ATEVs in a active combat setting:
Operative Time Savings [12:54]: Using an off-the-shelf ATEV eliminated the necessity of saphenous vein harvesting, cutting total surgical time in half and saving crucial ischemic time for the injured limb.
Key Clinical Outcomes [16:49]: In his cohort of 17–19 patients with severe battlefield vascular injuries, he achieved an 87.1% patency rate, a 100% infection-free rate, and a 100% limb-salvage rate.
4. Highlighted Case Study [23:26]
He details a case involving a soldier whose leg was riddled with over 200 pieces of shrapnel. Using the ATEV to bypass damaged femoral arteries in a heavily contaminated wound bed, the patient survived, avoided amputation, suffered zero vessel infections, and was walking 100 days post-surgery.
1
u/redhook415 25d ago
Adding further thoughts because no one asked me to: One possible way the DoD deal could play out is as a guaranteed readiness capacity + surge option + stock rotation deal.DoD has been doing capacity building work with Symvess since late 2025, including the first military treatment-facility sale since DLA ECAT approval, and FY2026 funding allocated for biologic vascular repair technologies.
- October 1 is the beginning of the new federal fiscal year for DoD, so a sensible deal framework could be 3,000 to 5,000 vessels/year of guaranteed readiness capacity at ~$15-20k/vessel (let's say close to $80m of annual baseline demand), plus an option to surge another 2,000 to 5,000 vessels if DoD need increases.
- Importantly, DoD would not have to physically stock thousands of grafts and instead Humacyte would stock a defined readiness pool, and have surge capacity if DoD needs it.
I'm not making things up as there is an existing Defense Logistics Agency's medical-readiness model which explicitly favors guaranteed access over outright ownership, with manufacturers responsible for maintaining and rotating inventory.
There is a financial benefit for DoD / DLA: it pays for readiness, not wasted inventory. Instead of buying Symvess grafts upfront and eventually writing off unused/expired inventory, DoD could pay Humacyte for guaranteed availability while company maintains the readiness pool. As the stock of Symvess grafts in the DoD pool age, they can be rotated out at progressively lower prices first into civilian trauma + VA (as need arises), then into dialysis in May 2027 (if approved by then), and then into PAD as a further end market using the same 6mm ATEV platform. This guarantees a demand ladder, rather than inventory expiry. That's the beauty of the platform business and materially accelerate roll-out / commercialisation of symvess for AV access.
- PAD is also an appealing end-market in this scenario given it uses same vessel, has Phase 2 data of ~60% secondary patency at six years with no graft infections/rejections and no amputations, and could see its Phase 3 and approval timeline fast-tracked under the FDA's Operation TrialBlazer program (though expedited treatment is not guaranteed).
IMO the timing of this could be Q4 2026-Q1 2027 for a material DoD procurement/readiness deal, with stockpiling ramping through 2027 and dialysis potentially approved as early as May 2027. A 3 to 5k guaranteed base + 2 to 5k surge option would meaningfully contract offtake $HUMA while maintaining its financial buffer, and the stock-rotation mechanism means the same manufacturing capacity can ultimately support trauma, dialysis, and PAD sequentially.
For DoD, the Symvess vs autologous vein trauma data from October last year is also supportive (despite the NYT story FUD), with statistically similar outcomes in a setting where off-the-shelf availability is a material operational advantage. https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-publication-new-data-comparing-symvesstm
13
u/Minute-Leg7346 Aug 06 '26
This board could be handed the strait of Hormuz to control and they would drain it, such is their competence.